La Revue de medecine interne · 1999
[Taxotere as second-line for metastatic breast cancer].
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Culine S
Аннотация
INTRODUCTION: Due its palliative effects, chemotherapy for breast cancer has two main objectives: disease control for as long as possible and optimal quality of life. Standard first-line treatment includes currently combination regimens with anthracyclines. What is the impact of docetaxel (Taxotere) now available for treatment in case of failure of anthracycline-based regimens?
CURRENT KNOWLEDGE AND KEY POINTS: Preliminary results of randomized phase III trials suggest higher levels of efficacy with docetaxel than those observed with other drugs used so far. Docetaxel toxicity is moderate. Its main side-effects are neutropenia and alopecia. The incidence of the peculiar docetaxel-related fluid retention syndrome has been shown to be delayed by prophylactic corticotherapy.
FUTURE PROSPECTS AND PROJECTS: Further studies are required to assess the impact of docetaxel in combination regimens as well as for the overall management of breast cancer.
CURRENT KNOWLEDGE AND KEY POINTS: Preliminary results of randomized phase III trials suggest higher levels of efficacy with docetaxel than those observed with other drugs used so far. Docetaxel toxicity is moderate. Its main side-effects are neutropenia and alopecia. The incidence of the peculiar docetaxel-related fluid retention syndrome has been shown to be delayed by prophylactic corticotherapy.
FUTURE PROSPECTS AND PROJECTS: Further studies are required to assess the impact of docetaxel in combination regimens as well as for the overall management of breast cancer.